Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    fecal transplant | severe acute malnutrition
Previous Study | Return to List | Next Study

Transfer of Healthy Gut Flora for Restoration of Intestinal Microbiota Via Enema for Patients in the Rehabilitative Phase of Malnutrition (THRIVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03087097
Recruitment Status : Active, not recruiting
First Posted : March 22, 2017
Last Update Posted : April 15, 2020
Sponsor:
Collaborator:
University of Cape Town
Information provided by (Responsible Party):
Microbiome Health Research Institute

Brief Summary:

This single-center, randomized, open-label trial will compare the safety of MTT delivered by rectal catheter enema in participants 12-60 months of age with malnutrition (moderate acute malnutrition [MAM] or severe acute malnutrition [SAM]) who are in the rehabilitative phase of treatment and have failed to respond to at least 4 weeks of standard therapy. Participants must meet inclusion criteria, no exclusion criteria prior to randomization. Participants will then be randomized in a 1:1 ratio at each site to 1 of 2 treatment groups:

  • MTT by rectal catheter enema: 10mL/kg (maximum 150mL, +/- 5ml) of healthy donor human intestinal microbiota will be infused.
  • Standard of care treatment for malnutrition as prescribed by local and national Department of Health Guidelines Participants will be evaluated through 56 days (±3) after randomization for primary outcomes (safety) as well as secondary outcomes (nutritional, clinical and microbiological response).

Participant blood and urine samples will be collected at enrollment and day 56. Participant stool samples will be collected at enrollment and through days 3, 7, 21 and 56, thereafter, 3 months, 4 months, and 6 months. A caregiver stool sample will be collected at enrollment and day 56. Samples will be used for microbiome determination and other exploratory microbiological endpoints. An aliquot of donor stool will also be stored for microbiome determination and other exploratory microbiological endpoints and assessment of newly acquired infectious agents.


Condition or disease Intervention/treatment Phase
Severe Acute Malnutrition Moderate Acute Malnutrition Biological: Fecal Microbiota Transplantation Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Transfer of Healthy Gut Flora for Restoration of Intestinal Microbiota Via Enema (THRIVE) for Patients in the Rehabilitative Phase of Malnutrition: A Pilot Study Evaluating Microbial Engraftment, Safety and Nutritional Outcomes
Actual Study Start Date : April 11, 2019
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Fecal Microbiota Transplant
FMT by enema: 10mL/kg (maximum 150mL) of healthy donor human intestinal microbiota will be infused.
Biological: Fecal Microbiota Transplantation
Fecal microbiota delivered by rectal catheter enema in participants 12-60 months of age with malnutrition (MAM or SAM) who are in the rehabilitation phase of treatment and have failed to respond to at least 4 weeks of standard therapy.
Other Name: Microbiota transfer therapy (MTT)

No Intervention: Standard of Care
Standard of care treatment for malnutrition as prescribed by local and national Department of Health Guidelines



Primary Outcome Measures :
  1. Serious Adverse Events [ Time Frame: 56 days ]
    Number of participants with an Adverse Event grade 2 or above up to 56 days post-treatment


Secondary Outcome Measures :
  1. Nutritional recovery: [ Time Frame: 56 days ]
    Proportion of participants with nutritional recovery at day 56 after randomization. Defined as weight for height z-score (WHZ) ≥ -2 or MUAC ≥ 125 mm. In cases where there is a significant discrepancy between the weight and MUAC the participants weight will be used as the definitive measure.

  2. Clinical: [ Time Frame: 56 days ]
    Presence of signs and symptoms or complications of acute malnutrition. Clinical signs include fever (axillary temperature > 38.5⁰C), tachypnea (average of two measures; defined as respiratory rate of > 40 breaths per minute for children 12-60 months of age). Symptoms include diarrhea (≥ 3 loose stools in the last 24 hours), vomiting, and cough.

  3. Microbiological: [ Time Frame: 56 Days ]
    Assess engraftment of donor microbial communities in recipients through taxonomic characterization of donor and recipient microbiota pre- and post-MTT using both 16S rRNA and metagenomic techniques.

  4. Translational: [ Time Frame: 56 Days ]
    Assess the capacity for MTT to normalize biomarkers correlated with disease status and mortality in malnutrition. Stool biomarkers include Myeloperoxidase, Alpha-1-Antitrypsin, fecal calprotectin and neopterin. Serological biomarkers include CRP, endotoxin assay (Hek-Blue), and leptin.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Months to 60 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Participant Inclusion Criteria

Participants eligible to participate in this study must meet the following inclusion criteria:

  1. Age 12 to 60 months.
  2. Current diagnosis of malnutrition (defined as a WHZ less than -2 according to the WHO 2006 standards or a MUAC less than 125mm) with failure to respond nutritionally, defined as:

    a. A WHZ of less than −2 according or a mid-upper-arm circumference of less than 125 mm i. No medical complications present ii. Participant is sufficiently alert and successfully passes the appetite test which involves consumption of breastmilk or a ready to use therapeutic food (RUTF) under supervision.

    iii. Participant is in the rehabilitation phase of treatment for malnutrition

  3. HIV negative
  4. Received at last four weeks of optimal WHO treatment for malnutrition:

    1. Micronutrient supplementation (Vitamin A, zinc and iron) as recommended by local guidelines
    2. Nutritional rehabilitation as recommended by local guidelines.
  5. Written informed consent obtained by parent or caregiver.

Participant Exclusion Criteria

Participants will not be able to participate if they meet any of the following exclusion criteria:

  1. Evidence of current complicated malnutrition defined as any of the following:

    1. Admitted to acute care ward as inpatient
    2. Signs of severe acute infection such as pneumonia, bacteremia, meningitis. Minor infections such as candida dermatitis, pharyngitis, upper respiratory tract infections will be eligible for inclusion at the discretion of the study physician.
    3. One or more WHO Integrated Management of Childhood Illness danger signs.(3)
    4. Failure to pass appetite test.
    5. Presence of known comorbid diseases such as pulmonary Tuberculosis on treatment, cystic fibrosis, type I diabetes mellitus, intestinal malabsorptive syndromes, chronic lung disease, chronic liver disease, chronic renal disease, chronic neurological diseases (e.g. cerebral palsy) or malignancy undergoing active chemotherapy.
    6. Bilateral pitting pedal edema or generalized anasarca
  2. Have taken antibiotics in the past seven days before the Day 0 visit or are anticipated to need antibiotics up to seven days before the Day 0 visit.
  3. Congenital malformations, syndromic conditions, and congenital metabolic abnormalities (inborn errors of metabolism) that may adversely affect growth and in the view of the clinician, exposes the child to increased risk.

    a. Fetal alcohol syndrome (FAS) is not an exclusion.

  4. Presence of bilateral pitting edema Grade 2.
  5. Contraindications to rectal catheter enema:

    1. Anorectal malformations
    2. Rectal prolapse
    3. Hirschsprungs disease
    4. Other contraindication to enema.
  6. Primary immune deficiencies
  7. Acute, persistent or chronic diarrhea.
  8. Dysentery
  9. Intestinal abnormalities including malformations, Hirschsprungs disease and short bowel syndrome
  10. Any condition that the physician investigators deems unsafe, including other conditions or medications that the investigator determines puts the participant at greater risk from MTT

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03087097


Locations
Layout table for location information
South Africa
University of Cape Town
Cape Town, South Africa
Sponsors and Collaborators
Microbiome Health Research Institute
University of Cape Town
Investigators
Layout table for investigator information
Principal Investigator: Majdi A Osman, MD MPH Microbiome Health Research Institute
Principal Investigator: Shrish Budree, MD MBChB DCH FCPeds Microbiome Health Research Institute
Layout table for additonal information
Responsible Party: Microbiome Health Research Institute
ClinicalTrials.gov Identifier: NCT03087097    
Other Study ID Numbers: THRIVE001
First Posted: March 22, 2017    Key Record Dates
Last Update Posted: April 15, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Microbiome Health Research Institute:
SAM
MAM
Additional relevant MeSH terms:
Layout table for MeSH terms
Malnutrition
Severe Acute Malnutrition
Nutrition Disorders